Carcinoma, Non-Small-Cell Lung (NSCLC) Clinical Trials

5 recruitingLast updated: July 25, 2026

There are 5 actively recruiting carcinoma, non-small-cell lung (nsclc) clinical trials across 33 countries. Studies span Phase 3, Phase 2. Top locations include New Lenox, Illinois, United States, Hinsdale, Illinois, United States, Athens, Greece. Updated daily from ClinicalTrials.gov.


Carcinoma, Non-Small-Cell Lung (NSCLC) Trials at a Glance

5 actively recruiting trials for carcinoma, non-small-cell lung (nsclc) are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 3 with 2 trials, with the heaviest enrollment activity in New Lenox, Hinsdale, and Athens. Lead sponsors running carcinoma, non-small-cell lung (nsclc) studies include Pfizer, Centre Antoine Lacassagne, and Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo.

Browse carcinoma, non-small-cell lung (nsclc) trials by phase

Treatments under study

About Carcinoma, Non-Small-Cell Lung (NSCLC) Clinical Trials

Looking for clinical trials for Carcinoma, Non-Small-Cell Lung (NSCLC)? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Carcinoma, Non-Small-Cell Lung (NSCLC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Carcinoma, Non-Small-Cell Lung (NSCLC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 15 of 5 trials

Recruiting
Phase 3

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Lung CancerNon-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+3 more
Pfizer1,410 enrolled413 locationsNCT07222566
Recruiting
Phase 3

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Non-small Cell Lung CancerCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer714 enrolled372 locationsNCT06758401
Recruiting

Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib

Lung AdenocarcinomaDepressionCognitive Dysfunction+3 more
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo24 enrolled1 locationNCT07633626
Recruiting
Phase 2

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Non-small Cell Lung CancerLung NeoplasmsCarcinoma+6 more
Pfizer120 enrolled3 locationsNCT07489066
Recruiting

Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma

Carcinoma, Non-Small-Cell Lung (NSCLC)
Centre Antoine Lacassagne200 enrolled1 locationNCT06833229